Production (Stage)
Maze Therapeutics, Inc.
MAZE
$12.93
-$0.41-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 2.50M | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | 0.00 | 2.50M | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | 0.00 | 2.50M | -- | |
| SG&A Expenses | 7.82M | 7.51M | 6.87M | 6.14M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 35.40M | 29.73M | 26.73M | 28.01M | |
| Operating Income | -35.40M | -29.73M | -24.23M | -28.01M | |
| Income Before Tax | -32.79M | -29.85M | -25.03M | -32.49M | |
| Income Tax Expenses | -- | -275.00K | -279.00K | -- | |
| Earnings from Continuing Operations | -32.79M | -29.58M | -24.75M | -32.49M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -32.79M | -29.58M | -24.75M | -32.49M | |
| EBIT | -35.40M | -29.73M | -24.23M | -28.01M | |
| EBITDA | -34.72M | -29.02M | -23.44M | -27.06M | |
| EPS Basic | -1.15 | -2.02 | -1.00 | -13.91 | |
| Normalized Basic EPS | -0.72 | -7.25 | -5.76 | -7.42 | |
| EPS Diluted | -1.15 | -2.31 | -1.00 | -13.91 | |
| Normalized Diluted EPS | -0.72 | -7.25 | -5.76 | -7.42 | |
| Average Basic Shares Outstanding | 28.63M | 2.43M | 2.43M | 2.34M | |
| Average Diluted Shares Outstanding | 28.63M | 2.43M | 2.43M | 2.34M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |